George Goshua, MD, MSc, FACP
Hematology
Biography
George Goshua, MD, MSc, FACP, is a physician-scientist who specializes in hematology, diagnosing and treating various blood disorders, such as thrombosis and anemia.
Dr. Goshua runs the first health decision science laboratory focused on hematology-oncology outcomes in the United States. His research has been repeatedly awarded by the leading hematology societies, the NOMIS Foundation, and Science Magazine.
Dr. Goshua is an assistant professor of medicine at Yale School of Medicine.
Titles
- Assistant Professor of Medicine (Hematology)
Education & Training
- MScHarvard T.H. Chan School of Public Health, Risk and Decision Science (Department of Health Policy & Management) (2022)
- Clinical Fellow (Hematology)Yale School of Medicine (2022)
- Instructor of Medicine and Chief Medical ResidentYale School of Medicine (2019)
- ResidentYale School of Medicine (2018)
- MDUniversity of Kentucky College of Medicine (2015)
- BSc (Hon)University of Toronto, Neuroscience & Physiology Double Major, Forest Conservation Minor (2010)
Additional Information
Honors & Recognitions
- Top Reviewer [2023 Calendar Year]: Annals of Internal Medicine (2024)
- NOMIS & Science Young Explorer Award: NOMIS Foundation and Science Magazine (2023)
- Top Reviewer [2022 Calendar Year]: Annals of Internal Medicine (2023)
- 2022 Young Investigator Award [Finalist]: American Journal of Hematology (2023)
- 2021 Young Investigator Award: American Journal of Hematology (2022)
- 2021-2022 Bernard G. Forget Scholar: Yale Hematology (2021)
- Junior AΩA (2014): Alpha Omega Alpha Honor Medical Society (2014)
- Gold Humanism Honor Society (2014): Arnold P. Gold Foundation (2014)
Board Certifications
- AB of Internal Medicine, Hematology (Internal Medicine) (2022)
- AB of Internal Medicine, Internal Medicine (2018)
Publications
- Ito S, Pandya A, Hauser R, Krishnamurti L, Stites E, Tormey C, Krumholz H, Hendrickson J, Goshua G. Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource. American Journal Of Hematology 2024, 99: 570-576. PMID: 38279581, DOI: 10.1002/ajh.27211.
- Wang D, Ito S, Waldron C, Butt A, Zhang E, Krumholz H, Al-Samkari H, Goshua G. Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia. Blood Advances 2024, 8: 2835-2845. PMID: 38537061, PMCID: PMC11176968, DOI: 10.1182/bloodadvances.2024012589.
- Allen C, Ito S, Butt A, Purcell A, Richmond R, Tormey C, Krumholz H, Cuker A, Goshua G. Cost-effectiveness of rapid vs in-house vs send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura. Blood Advances 2024, 8: 2279-2289. PMID: 38502197, PMCID: PMC11116991, DOI: 10.1182/bloodadvances.2024012608.
- Goshua G. Napkin math can change the world. Science 2023, 382: 657-657. PMID: 37943923, DOI: 10.1126/science.adk8633.
- Goshua G, Calhoun C, Ito S, James L, Luviano A, Krishnamurti L, Pandya A. Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States. Annals Of Internal Medicine 2023, 176: 779-787. PMID: 37247420, PMCID: PMC10370480, DOI: 10.7326/m22-3272.
- Potnis K, Viswanathan G, Bona R, Ito S, Kempton C, Pandya A, Krumholz H, Goshua G. Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States. American Journal Of Hematology 2023, 98: e247-e250. PMID: 37401660, DOI: 10.1002/ajh.27014.
- Ito S, Goshua G. Apixaban at Apex? Aligning Drug Pricing With Value in Cancer-Associated Thrombosis. Annals Of Internal Medicine 2022, 176: 125-126. PMID: 36571840, DOI: 10.7326/m22-3404.
- Goshua G, Sinha P, Kunst N, Pischel L, Lee AI, Cuker A. Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia. American Journal Of Hematology 2022, 98: 122-130. PMID: 35147241, PMCID: PMC9365880, DOI: 10.1002/ajh.26497.
- Pischel L, Goshua G. Cost-effectiveness of Tocilizumab in Severe Coronavirus Disease 2019: to See or Not to See. Clinical Infectious Diseases 2021, 73: 2119-2120. PMID: 33999992, PMCID: PMC8194546, DOI: 10.1093/cid/ciab459.
- Goshua G, Prasad V, Lee AI, Bendapudi PK. Accurate accounting of caplacizumab cost effectiveness. The Lancet Haematology 2021, 8: e315. PMID: 33894166, DOI: 10.1016/s2352-3026(21)00052-1.
- Goshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi PK, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 2021, 137: 969-976. PMID: 33280030, PMCID: PMC7918179, DOI: 10.1182/blood.2020006052.
- Stukas S, Goshua G, Kinkade A, Grey R, Mah G, Biggs CM, Jamal S, Thiara S, Lau TTY, Piszczek J, Partovi N, Sweet DD, Lee AYY, Wellington CL, Sekhon MS, Chen LYC. Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study. The Lancet Regional Health - Americas 2022, 11: 100228. PMID: 35345649, PMCID: PMC8941850, DOI: 10.1016/j.lana.2022.100228.
- Waldron C, Goshua G. Splenectomy reappraised: Bridging the gap in immune cytopenia treatment paradigms. Journal Of Internal Medicine 2023, 295: 120-122. PMID: 38044059, DOI: 10.1111/joim.13756.
- Pischel L, Martini B, Yu N, Cacesse D, Tracy M, Kharbanda K, Ahmed N, Patel K, Grimshaw A, Malik A, Goshua G, Omer S. Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis. Vaccine 2024, 42: 126053. PMID: 38906763, DOI: 10.1016/j.vaccine.2024.06.021.
- Mendiratta G, Liarakos D, Tong M, Ito S, Ke E, Goshua G, Stites E. Cancer research is not correlated with driver gene mutation burdens. Med 2024, 5: 832-838.e4. PMID: 38908369, DOI: 10.1016/j.medj.2024.05.013.
- Waldron C, Ito S, Wang D, Allen C, Viswanathan G, Bona R, Cuker A, Goshua G. Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States. Blood 2024, 143: 2332-2335. PMID: 38635764, DOI: 10.1182/blood.2024024209.
- Ito S, Wang D, Purcell A, Chetlapalli K, Lee A, Cuker A, Goshua G. Cost‐effectiveness of sutimlimab in cold agglutinin disease. American Journal Of Hematology 2024, 99: 1475-1484. PMID: 38733355, DOI: 10.1002/ajh.27358.
- Namineni N, Waldron C, Tormey C, Goshua G. Severe, Refractory Primary Warm Autoimmune Hemolytic Anemia Requiring 90 Erythrocyte Transfusions. Annals Of Internal Medicine Clinical Cases 2024, 3 PMID: 38725710, PMCID: PMC11081177, DOI: 10.7326/aimcc.2023.1141.
- Bewersdorf J, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Stahl M, Stein E, Huntington S, Goshua G, Zeidan A. Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia. Leukemia & Lymphoma 2024, 65: 1136-1144. PMID: 38648559, PMCID: PMC11265977, DOI: 10.1080/10428194.2024.2344052.
- Goshua G. Limitless. Journal Of General Internal Medicine 2024, 39: 2118-2119. PMID: 38499721, PMCID: PMC11306657, DOI: 10.1007/s11606-024-08724-8.
- Waldron C, Ito S, Wang D, Viswanathan G, Butt A, Goshua G. Second-Line Therapy Sequencing in Primary Warm Autoimmune Hemolytic Anemia: Splenectomy-Rituximab Versus Rituximab-Splenectomy. Blood 2023, 142: 2317. DOI: 10.1182/blood-2023-189957.
- Ito S, Potnis K, Allen C, Richmond R, Waldron C, Viswanathan G, Bona R, Goshua G. Equitable Care for Severe Hemophilia_A: Distributional Cost-Effectiveness of Prophylactic Weekly Efanesoctocog Alfa Versus Standard-Care Factor VIII in Patients with Severe Hemophilia_A in the United States. Blood 2023, 142: 492. DOI: 10.1182/blood-2023-190420.
- Waldron C, Ito S, Wang D, Allen C, Viswanathan G, Bona R, Cuker A, Goshua G. Cost-Effectiveness of Long-Term Prophylaxis with Plasma-Derived Vs. Recombinant Von Willebrand Factor in Severe Von Willebrand Disease. Blood 2023, 142: 3698. DOI: 10.1182/blood-2023-188018.
- Allen C, Ito S, Butt A, Purcell A, Richmond R, Cuker A, Goshua G. Cost-Effectiveness of Rapid Hemosil Versus in-House and Send-out ADAMTS13 Activity Testing in the Care of Patients with Immune Thrombotic Thrombocytopenic Purpura. Blood 2023, 142: 368. DOI: 10.1182/blood-2023-184927.
- Wang D, Ito S, Waldron C, Butt A, Zhang E, Krumholz H, Al-Samkari H, Goshua G. Longitudinal Systemic Bevacizumab Therapy Produces Cost Savings and Improves Quality-Adjusted Life Expectancy in the Care of Patients with Hereditary Hemorrhagic Telangiectasia with Moderate-to-Severe Bleeding. Blood 2023, 142: 2312. DOI: 10.1182/blood-2023-185340.
- Goshua G, Ito S, Chetlapalli K, Potnis K, Calhoun C, Krishnamurti L, Krumholz H, Pandya A. Allotransplantation and Gene Therapy Equity for Children with Sickle Cell Disease: Distributional Cost-Effectiveness of Allotransplantation Vs Gene Therapy Vs Standard-of-Care in Pediatric Patients with Sickle Cell Disease in the United States. Blood 2023, 142: 490. DOI: 10.1182/blood-2023-191072.
- Allen C, Streiff M, Naik R, Knauert M, Goshua G. Consecutive Inpatient Hematology Consultation Service Utilization across 11 Years in the Medical Intensive Care Unit. Blood 2023, 142: 2323. DOI: 10.1182/blood-2023-184891.
- Ito S, Wang D, Purcell A, Chetlapalli K, Lee A, Cuker A, Goshua G. Cost-Effectiveness of Sutimlimab Versus Standard-of-Care in Transfusion Dependent Patients with Primary Cold Agglutinin Disease in the United States. Blood 2023, 142: 2316. DOI: 10.1182/blood-2023-187270.
- Ito S, Chetlapalli K, Potnis K, Richmond R, Wang D, Lee A, Goshua G. Setting Cost-Effective Price Thresholds before FDA Approval: Cost-Effectiveness of Iptacopan Monotherapy Versus Standard-of-Care Anti-C5 Therapy in Transfusion-Dependent, Treatment-Experienced Adult Patients with Paroxysmal Nocturnal Hemoglobinuria in the United States. Blood 2023, 142: 5042. DOI: 10.1182/blood-2023-188063.
- Kewan T, Mirza S, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS). Blood 2023, 142: 2132. DOI: 10.1182/blood-2023-187295.
- Butt A, Allen C, Purcell A, Ito S, Goshua G. Global Health Resource Utilization and Cost-Effectiveness of Therapeutics and Diagnostics in Immune Thrombotic Thrombocytopenic Purpura (TTP). Journal Of Clinical Medicine 2023, 12: 4887. PMID: 37568288, PMCID: PMC10420213, DOI: 10.3390/jcm12154887.
- Goshua G, Lee A. Summiting thrombotic hazards in glioma. Blood 2023, 141: 1245-1246. PMID: 36929442, DOI: 10.1182/blood.2022019020.
- Goshua G, Bendapudi P. Evidence-Based Minireview: Should caplacizumab be used routinely in unselected patients with immune thrombotic thrombocytopenic purpura? Hematology 2022, 2022: 491-494. PMID: 36485149, PMCID: PMC9820987, DOI: 10.1182/hematology.2022000412.
- Goshua G, Bendapudi P, Lee A. Thrombosis questions from the inpatient wards. Hematology 2022, 2022: 481-490. PMID: 36485139, PMCID: PMC9819989, DOI: 10.1182/hematology.2022000384.
- Bewersdorf J, Patel K, Goshua G, Shallis R, Podoltsev N, Stahl M, Stein E, Huntington S, Zeidan A. Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia. Leukemia & Lymphoma 2022, 64: 454-461. PMID: 36493798, PMCID: PMC9957935, DOI: 10.1080/10428194.2022.2140288.
- Bewersdorf JP, Patel KK, Goshua G, Shallis RM, Podoltsev NA, Huntington SF, Zeidan AM. Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia. Blood 2022, 139: 1766-1770. PMID: 35298594, PMCID: PMC8931513, DOI: 10.1182/blood.2021014401.
- Pischel L, Patel KM, Goshua G, Omer SB. Adenovirus-Based Vaccines and Thrombosis in Pregnancy: A Systematic Review and Meta-analysis. Clinical Infectious Diseases 2022, 75: 1179-1186. PMID: 35134164, PMCID: PMC9383370, DOI: 10.1093/cid/ciac080.
- Goshua G, Butt A, Lee AI. Immunothrombosis: a COVID‐19 concerto. British Journal Of Haematology 2021, 194: 491-493. PMID: 34114208, DOI: 10.1111/bjh.17666.
- Ma L, Sahu S, Cano M, Kuppuswamy V, Bajwa J, McPhatter J, Pine A, Meizlish M, Goshua G, Chang C, Zhang H, Price C, Bahel P, Rinder H, Lei T, Day A, Reynolds D, Wu X, Schriefer R, Rauseo A, Goss C, O’Halloran J, Presti R, Kim A, Gelman A, Dela Cruz C, Lee A, Mudd P, Chun H, Atkinson J, Kulkarni H. Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. Science Immunology 2021, 6: eabh2259. PMID: 34446527, PMCID: PMC8158979, DOI: 10.1126/sciimmunol.abh2259.
- Meizlish ML, Pine AB, Bishai JD, Goshua G, Nadelmann ER, Simonov M, Chang CH, Zhang H, Shallow M, Bahel P, Owusu K, Yamamoto Y, Arora T, Atri DS, Patel A, Gbyli R, Kwan J, Won CH, Dela Cruz C, Price C, Koff J, King BA, Rinder HM, Wilson FP, Hwa J, Halene S, Damsky W, van Dijk D, Lee AI, Chun HJ. A neutrophil activation signature predicts critical illness and mortality in COVID-19. Blood Advances 2021, 5: 1164-1177. PMID: 33635335, PMCID: PMC7908851, DOI: 10.1182/bloodadvances.2020003568.
- Meizlish ML, Goshua G, Liu Y, Fine R, Amin K, Chang E, DeFilippo N, Keating C, Liu Y, Mankbadi M, McManus D, Wang SY, Price C, Bona RD, Chaar C, Chun HJ, Pine AB, Rinder HM, Siner JM, Neuberg DS, Owusu KA, Lee AI. Intermediate‐dose anticoagulation, aspirin, and in‐hospital mortality in COVID‐19: A propensity score‐matched analysis. American Journal Of Hematology 2021, 96: 471-479. PMID: 33476420, PMCID: PMC8013588, DOI: 10.1002/ajh.26102.
- Goshua G, Lee AI. Harmonizing hypercoagulable heterogeneity: Baseline VTE risk in COVID‐19. Research And Practice In Thrombosis And Haemostasis 2021, 5: e12448. PMID: 33537523, PMCID: PMC7845060, DOI: 10.1002/rth2.12448.
- Goshua G, Liu Y, Meizlish M, Fine R, Amin K, Chang E, Liu Y, McManus D, Petrosan A, Chaar C, Chun H, Defilippo N, Neuberg D, Owusu K, Lee A. Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis. Blood 2020, 136: 23-24. PMCID: PMC8330288, DOI: 10.1182/blood-2020-143349.
- Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, Dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. The Lancet Haematology 2020, 7: e575-e582. PMID: 32619411, PMCID: PMC7326446, DOI: 10.1016/s2352-3026(20)30216-7.
- Goshua G, Gokhale A, Hendrickson JE, Tormey C, Lee AI. Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura. Blood Advances 2020, 4: 539-545. PMID: 32045473, PMCID: PMC7013262, DOI: 10.1182/bloodadvances.2019000827.
- Goshua G. Shared Humanity. Annals Of Internal Medicine 2017, 167: 359. PMID: 28869981, DOI: 10.7326/m16-2602.
- Goshua G. Breathe. Journal Of General Internal Medicine 2016, 31: 974-975. PMID: 27145759, PMCID: PMC4945569, DOI: 10.1007/s11606-016-3702-6.
Departments and Programs
Biography
George Goshua, MD, MSc, FACP, is a physician-scientist who specializes in hematology, diagnosing and treating various blood disorders, such as thrombosis and anemia.
Dr. Goshua runs the first health decision science laboratory focused on hematology-oncology outcomes in the United States. His research has been repeatedly awarded by the leading hematology societies, the NOMIS Foundation, and Science Magazine.
Dr. Goshua is an assistant professor of medicine at Yale School of Medicine.
Titles
- Assistant Professor of Medicine (Hematology)
Education & Training
- MScHarvard T.H. Chan School of Public Health, Risk and Decision Science (Department of Health Policy & Management) (2022)
- Clinical Fellow (Hematology)Yale School of Medicine (2022)
- Instructor of Medicine and Chief Medical ResidentYale School of Medicine (2019)
- ResidentYale School of Medicine (2018)
- MDUniversity of Kentucky College of Medicine (2015)
- BSc (Hon)University of Toronto, Neuroscience & Physiology Double Major, Forest Conservation Minor (2010)
Additional Information
Honors & Recognitions
- Top Reviewer [2023 Calendar Year]: Annals of Internal Medicine (2024)
- NOMIS & Science Young Explorer Award: NOMIS Foundation and Science Magazine (2023)
- Top Reviewer [2022 Calendar Year]: Annals of Internal Medicine (2023)
- 2022 Young Investigator Award [Finalist]: American Journal of Hematology (2023)
- 2021 Young Investigator Award: American Journal of Hematology (2022)
- 2021-2022 Bernard G. Forget Scholar: Yale Hematology (2021)
- Junior AΩA (2014): Alpha Omega Alpha Honor Medical Society (2014)
- Gold Humanism Honor Society (2014): Arnold P. Gold Foundation (2014)
Board Certifications
- AB of Internal Medicine, Hematology (Internal Medicine) (2022)
- AB of Internal Medicine, Internal Medicine (2018)
Publications
- Ito S, Pandya A, Hauser R, Krishnamurti L, Stites E, Tormey C, Krumholz H, Hendrickson J, Goshua G. Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource. American Journal Of Hematology 2024, 99: 570-576. PMID: 38279581, DOI: 10.1002/ajh.27211.
- Wang D, Ito S, Waldron C, Butt A, Zhang E, Krumholz H, Al-Samkari H, Goshua G. Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia. Blood Advances 2024, 8: 2835-2845. PMID: 38537061, PMCID: PMC11176968, DOI: 10.1182/bloodadvances.2024012589.
- Allen C, Ito S, Butt A, Purcell A, Richmond R, Tormey C, Krumholz H, Cuker A, Goshua G. Cost-effectiveness of rapid vs in-house vs send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura. Blood Advances 2024, 8: 2279-2289. PMID: 38502197, PMCID: PMC11116991, DOI: 10.1182/bloodadvances.2024012608.
- Goshua G. Napkin math can change the world. Science 2023, 382: 657-657. PMID: 37943923, DOI: 10.1126/science.adk8633.
- Goshua G, Calhoun C, Ito S, James L, Luviano A, Krishnamurti L, Pandya A. Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States. Annals Of Internal Medicine 2023, 176: 779-787. PMID: 37247420, PMCID: PMC10370480, DOI: 10.7326/m22-3272.
- Potnis K, Viswanathan G, Bona R, Ito S, Kempton C, Pandya A, Krumholz H, Goshua G. Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States. American Journal Of Hematology 2023, 98: e247-e250. PMID: 37401660, DOI: 10.1002/ajh.27014.
- Ito S, Goshua G. Apixaban at Apex? Aligning Drug Pricing With Value in Cancer-Associated Thrombosis. Annals Of Internal Medicine 2022, 176: 125-126. PMID: 36571840, DOI: 10.7326/m22-3404.
- Goshua G, Sinha P, Kunst N, Pischel L, Lee AI, Cuker A. Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia. American Journal Of Hematology 2022, 98: 122-130. PMID: 35147241, PMCID: PMC9365880, DOI: 10.1002/ajh.26497.
- Pischel L, Goshua G. Cost-effectiveness of Tocilizumab in Severe Coronavirus Disease 2019: to See or Not to See. Clinical Infectious Diseases 2021, 73: 2119-2120. PMID: 33999992, PMCID: PMC8194546, DOI: 10.1093/cid/ciab459.
- Goshua G, Prasad V, Lee AI, Bendapudi PK. Accurate accounting of caplacizumab cost effectiveness. The Lancet Haematology 2021, 8: e315. PMID: 33894166, DOI: 10.1016/s2352-3026(21)00052-1.
- Goshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi PK, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 2021, 137: 969-976. PMID: 33280030, PMCID: PMC7918179, DOI: 10.1182/blood.2020006052.
- Stukas S, Goshua G, Kinkade A, Grey R, Mah G, Biggs CM, Jamal S, Thiara S, Lau TTY, Piszczek J, Partovi N, Sweet DD, Lee AYY, Wellington CL, Sekhon MS, Chen LYC. Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study. The Lancet Regional Health - Americas 2022, 11: 100228. PMID: 35345649, PMCID: PMC8941850, DOI: 10.1016/j.lana.2022.100228.
- Waldron C, Goshua G. Splenectomy reappraised: Bridging the gap in immune cytopenia treatment paradigms. Journal Of Internal Medicine 2023, 295: 120-122. PMID: 38044059, DOI: 10.1111/joim.13756.
- Pischel L, Martini B, Yu N, Cacesse D, Tracy M, Kharbanda K, Ahmed N, Patel K, Grimshaw A, Malik A, Goshua G, Omer S. Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis. Vaccine 2024, 42: 126053. PMID: 38906763, DOI: 10.1016/j.vaccine.2024.06.021.
- Mendiratta G, Liarakos D, Tong M, Ito S, Ke E, Goshua G, Stites E. Cancer research is not correlated with driver gene mutation burdens. Med 2024, 5: 832-838.e4. PMID: 38908369, DOI: 10.1016/j.medj.2024.05.013.
- Waldron C, Ito S, Wang D, Allen C, Viswanathan G, Bona R, Cuker A, Goshua G. Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States. Blood 2024, 143: 2332-2335. PMID: 38635764, DOI: 10.1182/blood.2024024209.
- Ito S, Wang D, Purcell A, Chetlapalli K, Lee A, Cuker A, Goshua G. Cost‐effectiveness of sutimlimab in cold agglutinin disease. American Journal Of Hematology 2024, 99: 1475-1484. PMID: 38733355, DOI: 10.1002/ajh.27358.
- Namineni N, Waldron C, Tormey C, Goshua G. Severe, Refractory Primary Warm Autoimmune Hemolytic Anemia Requiring 90 Erythrocyte Transfusions. Annals Of Internal Medicine Clinical Cases 2024, 3 PMID: 38725710, PMCID: PMC11081177, DOI: 10.7326/aimcc.2023.1141.
- Bewersdorf J, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Stahl M, Stein E, Huntington S, Goshua G, Zeidan A. Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia. Leukemia & Lymphoma 2024, 65: 1136-1144. PMID: 38648559, PMCID: PMC11265977, DOI: 10.1080/10428194.2024.2344052.
- Goshua G. Limitless. Journal Of General Internal Medicine 2024, 39: 2118-2119. PMID: 38499721, PMCID: PMC11306657, DOI: 10.1007/s11606-024-08724-8.
- Waldron C, Ito S, Wang D, Viswanathan G, Butt A, Goshua G. Second-Line Therapy Sequencing in Primary Warm Autoimmune Hemolytic Anemia: Splenectomy-Rituximab Versus Rituximab-Splenectomy. Blood 2023, 142: 2317. DOI: 10.1182/blood-2023-189957.
- Ito S, Potnis K, Allen C, Richmond R, Waldron C, Viswanathan G, Bona R, Goshua G. Equitable Care for Severe Hemophilia_A: Distributional Cost-Effectiveness of Prophylactic Weekly Efanesoctocog Alfa Versus Standard-Care Factor VIII in Patients with Severe Hemophilia_A in the United States. Blood 2023, 142: 492. DOI: 10.1182/blood-2023-190420.
- Waldron C, Ito S, Wang D, Allen C, Viswanathan G, Bona R, Cuker A, Goshua G. Cost-Effectiveness of Long-Term Prophylaxis with Plasma-Derived Vs. Recombinant Von Willebrand Factor in Severe Von Willebrand Disease. Blood 2023, 142: 3698. DOI: 10.1182/blood-2023-188018.
- Allen C, Ito S, Butt A, Purcell A, Richmond R, Cuker A, Goshua G. Cost-Effectiveness of Rapid Hemosil Versus in-House and Send-out ADAMTS13 Activity Testing in the Care of Patients with Immune Thrombotic Thrombocytopenic Purpura. Blood 2023, 142: 368. DOI: 10.1182/blood-2023-184927.
- Wang D, Ito S, Waldron C, Butt A, Zhang E, Krumholz H, Al-Samkari H, Goshua G. Longitudinal Systemic Bevacizumab Therapy Produces Cost Savings and Improves Quality-Adjusted Life Expectancy in the Care of Patients with Hereditary Hemorrhagic Telangiectasia with Moderate-to-Severe Bleeding. Blood 2023, 142: 2312. DOI: 10.1182/blood-2023-185340.
- Goshua G, Ito S, Chetlapalli K, Potnis K, Calhoun C, Krishnamurti L, Krumholz H, Pandya A. Allotransplantation and Gene Therapy Equity for Children with Sickle Cell Disease: Distributional Cost-Effectiveness of Allotransplantation Vs Gene Therapy Vs Standard-of-Care in Pediatric Patients with Sickle Cell Disease in the United States. Blood 2023, 142: 490. DOI: 10.1182/blood-2023-191072.
- Allen C, Streiff M, Naik R, Knauert M, Goshua G. Consecutive Inpatient Hematology Consultation Service Utilization across 11 Years in the Medical Intensive Care Unit. Blood 2023, 142: 2323. DOI: 10.1182/blood-2023-184891.
- Ito S, Wang D, Purcell A, Chetlapalli K, Lee A, Cuker A, Goshua G. Cost-Effectiveness of Sutimlimab Versus Standard-of-Care in Transfusion Dependent Patients with Primary Cold Agglutinin Disease in the United States. Blood 2023, 142: 2316. DOI: 10.1182/blood-2023-187270.
- Ito S, Chetlapalli K, Potnis K, Richmond R, Wang D, Lee A, Goshua G. Setting Cost-Effective Price Thresholds before FDA Approval: Cost-Effectiveness of Iptacopan Monotherapy Versus Standard-of-Care Anti-C5 Therapy in Transfusion-Dependent, Treatment-Experienced Adult Patients with Paroxysmal Nocturnal Hemoglobinuria in the United States. Blood 2023, 142: 5042. DOI: 10.1182/blood-2023-188063.
- Kewan T, Mirza S, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS). Blood 2023, 142: 2132. DOI: 10.1182/blood-2023-187295.
- Butt A, Allen C, Purcell A, Ito S, Goshua G. Global Health Resource Utilization and Cost-Effectiveness of Therapeutics and Diagnostics in Immune Thrombotic Thrombocytopenic Purpura (TTP). Journal Of Clinical Medicine 2023, 12: 4887. PMID: 37568288, PMCID: PMC10420213, DOI: 10.3390/jcm12154887.
- Goshua G, Lee A. Summiting thrombotic hazards in glioma. Blood 2023, 141: 1245-1246. PMID: 36929442, DOI: 10.1182/blood.2022019020.
- Goshua G, Bendapudi P. Evidence-Based Minireview: Should caplacizumab be used routinely in unselected patients with immune thrombotic thrombocytopenic purpura? Hematology 2022, 2022: 491-494. PMID: 36485149, PMCID: PMC9820987, DOI: 10.1182/hematology.2022000412.
- Goshua G, Bendapudi P, Lee A. Thrombosis questions from the inpatient wards. Hematology 2022, 2022: 481-490. PMID: 36485139, PMCID: PMC9819989, DOI: 10.1182/hematology.2022000384.
- Bewersdorf J, Patel K, Goshua G, Shallis R, Podoltsev N, Stahl M, Stein E, Huntington S, Zeidan A. Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia. Leukemia & Lymphoma 2022, 64: 454-461. PMID: 36493798, PMCID: PMC9957935, DOI: 10.1080/10428194.2022.2140288.
- Bewersdorf JP, Patel KK, Goshua G, Shallis RM, Podoltsev NA, Huntington SF, Zeidan AM. Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia. Blood 2022, 139: 1766-1770. PMID: 35298594, PMCID: PMC8931513, DOI: 10.1182/blood.2021014401.
- Pischel L, Patel KM, Goshua G, Omer SB. Adenovirus-Based Vaccines and Thrombosis in Pregnancy: A Systematic Review and Meta-analysis. Clinical Infectious Diseases 2022, 75: 1179-1186. PMID: 35134164, PMCID: PMC9383370, DOI: 10.1093/cid/ciac080.
- Goshua G, Butt A, Lee AI. Immunothrombosis: a COVID‐19 concerto. British Journal Of Haematology 2021, 194: 491-493. PMID: 34114208, DOI: 10.1111/bjh.17666.
- Ma L, Sahu S, Cano M, Kuppuswamy V, Bajwa J, McPhatter J, Pine A, Meizlish M, Goshua G, Chang C, Zhang H, Price C, Bahel P, Rinder H, Lei T, Day A, Reynolds D, Wu X, Schriefer R, Rauseo A, Goss C, O’Halloran J, Presti R, Kim A, Gelman A, Dela Cruz C, Lee A, Mudd P, Chun H, Atkinson J, Kulkarni H. Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. Science Immunology 2021, 6: eabh2259. PMID: 34446527, PMCID: PMC8158979, DOI: 10.1126/sciimmunol.abh2259.
- Meizlish ML, Pine AB, Bishai JD, Goshua G, Nadelmann ER, Simonov M, Chang CH, Zhang H, Shallow M, Bahel P, Owusu K, Yamamoto Y, Arora T, Atri DS, Patel A, Gbyli R, Kwan J, Won CH, Dela Cruz C, Price C, Koff J, King BA, Rinder HM, Wilson FP, Hwa J, Halene S, Damsky W, van Dijk D, Lee AI, Chun HJ. A neutrophil activation signature predicts critical illness and mortality in COVID-19. Blood Advances 2021, 5: 1164-1177. PMID: 33635335, PMCID: PMC7908851, DOI: 10.1182/bloodadvances.2020003568.
- Meizlish ML, Goshua G, Liu Y, Fine R, Amin K, Chang E, DeFilippo N, Keating C, Liu Y, Mankbadi M, McManus D, Wang SY, Price C, Bona RD, Chaar C, Chun HJ, Pine AB, Rinder HM, Siner JM, Neuberg DS, Owusu KA, Lee AI. Intermediate‐dose anticoagulation, aspirin, and in‐hospital mortality in COVID‐19: A propensity score‐matched analysis. American Journal Of Hematology 2021, 96: 471-479. PMID: 33476420, PMCID: PMC8013588, DOI: 10.1002/ajh.26102.
- Goshua G, Lee AI. Harmonizing hypercoagulable heterogeneity: Baseline VTE risk in COVID‐19. Research And Practice In Thrombosis And Haemostasis 2021, 5: e12448. PMID: 33537523, PMCID: PMC7845060, DOI: 10.1002/rth2.12448.
- Goshua G, Liu Y, Meizlish M, Fine R, Amin K, Chang E, Liu Y, McManus D, Petrosan A, Chaar C, Chun H, Defilippo N, Neuberg D, Owusu K, Lee A. Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis. Blood 2020, 136: 23-24. PMCID: PMC8330288, DOI: 10.1182/blood-2020-143349.
- Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, Dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. The Lancet Haematology 2020, 7: e575-e582. PMID: 32619411, PMCID: PMC7326446, DOI: 10.1016/s2352-3026(20)30216-7.
- Goshua G, Gokhale A, Hendrickson JE, Tormey C, Lee AI. Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura. Blood Advances 2020, 4: 539-545. PMID: 32045473, PMCID: PMC7013262, DOI: 10.1182/bloodadvances.2019000827.
- Goshua G. Shared Humanity. Annals Of Internal Medicine 2017, 167: 359. PMID: 28869981, DOI: 10.7326/m16-2602.
- Goshua G. Breathe. Journal Of General Internal Medicine 2016, 31: 974-975. PMID: 27145759, PMCID: PMC4945569, DOI: 10.1007/s11606-016-3702-6.
Departments and Programs